Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX07 +/- HLX10 in mCRC
NCT05239650Phase 2Not yet recruiting
- Sponsor
- Henlius
- Start
- Jul 2022
- Primary completion
- Oct 2025
- Modality
- Immune Checkpoint Inhibitors
01
Overview
Phase 2, open-label trial of pimurutamab and serplulimab in metastatic colorectal cancer (mCRC) (2 arms), sponsored by Henlius. Primary endpoints: Objective Response Rate up to 3 years and Progression-Free Survival up to 3 years. Planned start Jul 2022; status: not yet recruiting.
02
Drugs
pimurutamabserplulimab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT05239650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05239650.